Mount Sinai Health System is to implement an AI-powered analytics platform to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors.
As a National Cancer Institute-designated Comprehensive Cancer Center, Mount Sinai supports care for more than 4,000 oncology patients per year. In a move announced at the AACR Annual Meeting in San Diego, the center will use an AI-powered platform to support its cancer research and run genomic testing for patients. The platform will analyze blood cancers and solid tumors, detecting complex genomic variants that inform treatment decisions.
The platform condenses a traditionally time-intensive, manual process into a single analytic workflow, reducing hands-on analysis time and enhancing testing turnaround time. Hours of recovered clinician time can then be dedicated to making more informed treatment plans and patient-specific decisions.
John Carey, Managing Director, North America at SOPHiA GENETICS, says, “Mount Sinai is one of the most respected academic health systems in the United States, and we are proud to support them in providing care for more than 4,000 oncology patients each year. SOPHiA DDM™ is designed to change what is clinically possible at the point where it matters most – the moment a clinician is deciding how to treat a patient with cancer.”
“Complex genomic variants that would previously have required days of manual interpretation can now be identified, contextualized, and acted upon within a single platform. For a patient with a blood cancer or a solid tumor, that means a faster path to the right treatment, fewer delays between diagnosis and decision, and a care team that is working from deeper, more precise genomic insights than was previously achievable.”
“Institutions of Mount Sinai's caliber are not adopting AI tools for operational efficiency alone; they are doing so because the quality of the insights improves outcomes for the people in their care.”
Mount Sinai joins a growing network of institutions around the world that are choosing decentralized platforms to democratize data-driven medicine and accelerate precision oncology.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
